IMRX News

The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more

Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, raised $113 million by offering 7.5 million shares at $15, within the range of $14 to $16. The company offered 0.5 million more shares than anticipated. Immuneering's oncology programs target mutations of the MAPK and mTOR pathways, which run parallel to each other and are...read more

Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $105 million by offering 7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Immuneering would command a fully diluted market value of $391 million. ...read more

Immuneering, a preclinical biotech targeting signaling pathways to treat cancer and neurological diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Immuneering's oncology programs target mutations of the MAPK and mTOR pathways, which run parallel to each other and are inappropriately activated in over half of all cancers. The...read more